Despite the fact that androgen treatment also induced ATM phosphorylation in prostate cancer cells (LNCaP), we were unable to detect any changes in the phosphorylation level of Chk1/2 or H2AX proteins, suggesting that the ATM DNA damage checkpoint can only be partially activated in prostate cancer cells. Here, CHEK1 is linked to prostate carcinoma.